Foscarnet
Primary Systemic Amyloidosis
City of Hope Medical CenterSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Primary Systemic Amyloidosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Margarida Magalhaes-Silverman | Phase 2 | B |
CIS-DIAMMINEDICHLOROPLATINUM II Margarida Magalhaes-Silverman | Phase 2 | B |
Inno-206 Margarida Magalhaes-Silverman | Phase 2 | B |
Evomela Margarida Magalhaes-Silverman | Phase 2 | B |
DEXAMETHASONE Margarida Magalhaes-Silverman | Phase 2 | B |
View all 24 →
Same molecule, other indications
Foscarnet is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →